- Home
- GOSS vs NUS Comparison
GOSS vs NUS Comparison
Compare GOSS & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- NUS
- Stock Information
- Founded
- GOSS 2015
- NUS 1984
- Country
- GOSS United States
- NUS United States
- Employees
- GOSS N/A
- NUS N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- NUS Other Pharmaceuticals
- Sector
- GOSS Health Care
- NUS Health Care
- Exchange
- GOSS Nasdaq
- NUS Nasdaq
- Market Cap
- GOSS 585.9M
- NUS 603.4M
- IPO Year
- GOSS 2019
- NUS 1996
- Fundamental
- Price
- GOSS $2.41
- NUS $10.63
- Analyst Decision
- GOSS Strong Buy
- NUS Hold
- Analyst Count
- GOSS 6
- NUS 2
- Target Price
- GOSS $8.60
- NUS $6.88
- AVG Volume (30 Days)
- GOSS 3.7M
- NUS 645.4K
- Earning Date
- GOSS 11-06-2025
- NUS 11-06-2025
- Dividend Yield
- GOSS N/A
- NUS 2.26%
- EPS Growth
- GOSS N/A
- NUS N/A
- EPS
- GOSS N/A
- NUS 2.03
- Revenue
- GOSS $40,237,000.00
- NUS $1,626,325,000.00
- Revenue This Year
- GOSS N/A
- NUS N/A
- Revenue Next Year
- GOSS $34.10
- NUS $0.98
- P/E Ratio
- GOSS N/A
- NUS $5.23
- Revenue Growth
- GOSS N/A
- NUS N/A
- 52 Week Low
- GOSS $0.66
- NUS $5.32
- 52 Week High
- GOSS $3.60
- NUS $14.62
- Technical
- Relative Strength Index (RSI)
- GOSS 44.51
- NUS 40.23
- Support Level
- GOSS $2.25
- NUS $10.31
- Resistance Level
- GOSS $2.61
- NUS $12.59
- Average True Range (ATR)
- GOSS 0.18
- NUS 0.48
- MACD
- GOSS -0.05
- NUS -0.19
- Stochastic Oscillator
- GOSS 24.58
- NUS 15.56
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.